Actuate Therapeutics, Inc.
ACTU
$6.91
$0.213.13%
| Weiss Ratings | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.03% | |||
| 30-Day Total Return | -13.19% | |||
| 60-Day Total Return | -17.05% | |||
| 90-Day Total Return | -22.36% | |||
| Year to Date Total Return | -13.19% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -42.88% | |||
| 52-Week Low % Change | 21.60% | |||
| Price | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $11.73 | |||
| 52-Week Low Price | $5.51 | |||
| 52-Week Low Price (Date) | Sep 25, 2024 | |||
| 52-Week High Price (Date) | Jan 23, 2025 | |||
| Valuation | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 130.86M | |||
| Enterprise Value | 122.22M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -10.49 | |||
| Earnings Per Share Growth | -38.99% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1,264.15 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $6.91 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -4.86 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 19.55M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 817 887 8455 | |||
| Address | 1751 River Run Fort Worth, TX 76107 | |||
| Website | actuatetherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -255.41% | |||
| Return on Equity | -- | |||
| Income Statement | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -25.16M | |||
| Net Income (TTM) | -27.29M | |||
| Net Income Avl. to Common (TTM) | -27.29M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 15.32% | |||
| EPS Diluted (TTM) | -10.49 | |||
| EPS Diluted Growth (Q YOY) | 93.49% | |||
| Balance Sheet | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 8.64M | |||
| Cash Per Share (Q) | $0.44 | |||
| Total Current Assets (Q) | 9.21M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 104.20K | |||
| Current Ratio (Q) | 1.046 | |||
| Book Value Per Share (Q) | $0.01 | |||
| Total Assets (Q) | 9.32M | |||
| Total Current Liabilities (Q) | 8.80M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 9.21M | |||
| Total Common Equity (Q) | 104.20K | |||
| Cash Flow | ACTU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 27.53M | |||
| Net Change in Cash (TTM) | 5.68M | |||
| Levered Free Cash Flow (TTM) | -10.41M | |||
| Cash from Operations (TTM) | -21.84M | |||
